AstraZeneca's top products based on revenue 2016-2019

AstraZeneca is a global biopharmaceutical company with several leading pharmaceutical products. As of 2019, AstraZeneca’s top pharmaceutical product by revenue was Tagrisso, a medication used in the treatment of non-small-cell lung carcinomas. During that year, Tagrisso generated nearly 3.2 billion U.S. dollars in revenue for the company. The second-highest revenue generator for AstraZeneca in the same year was Symbicort, an inhaler used in the treatment of asthma and COPD. Symbicort generated about 2.5 billion U.S. dollars in revenue for the company during that year.

AstraZeneca company profile

AstraZeneca is a global pharmaceutical company with many employees all over the world. As of 2019, the highest proportion of AstraZeneca’s employees were based in the Asia-Pacific region. The global office and corporate headquarters of AstraZeneca is located in Cambridge in the United Kingdom. As of 2019, emerging markets and the U.S. market accounted for the highest revenues for AstraZeneca. The company is a leader in research and development globally as well.

AstraZeneca’s R&D

AstraZeneca has many research and development programs that are focused on addressing three main areas, oncology, cardiovascular, renal and metabolic diseases, and respiratory disease. AstraZeneca’s research and development expenditures have increased in recent years. In 2019, 25.7 percent of AstraZeneca’s total revenue was expended on research and development. And, as of early 2019, AstraZeneca was projected to be among the world’s top five pharmaceutical companies according to the number of drugs they had under development at that time.

Top products of AstraZeneca based on revenue from 2016 to 2019

Exclusive Premium statistic

You need a Single Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Single Account

only $59 / month *
in the first 12 months
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

March 2020



Survey time period

2016 to 2019

Supplementary notes

This statistic was assembled from several editions of AstraZeneca's annual reports.

Open this statistic in...
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account.

Single Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references
$59 / Month *
Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract; Prices do not include sales tax.

Statistics on "Pharmaceutical brands: Crestor and Nexium (AstraZeneca)"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.